CL2016003260A1 - Profármacos de gemcitabina - Google Patents

Profármacos de gemcitabina

Info

Publication number
CL2016003260A1
CL2016003260A1 CL2016003260A CL2016003260A CL2016003260A1 CL 2016003260 A1 CL2016003260 A1 CL 2016003260A1 CL 2016003260 A CL2016003260 A CL 2016003260A CL 2016003260 A CL2016003260 A CL 2016003260A CL 2016003260 A1 CL2016003260 A1 CL 2016003260A1
Authority
CL
Chile
Prior art keywords
gemcitabine
gemcitabine prodrugs
prodrugs
alaninyl
benzoxy
Prior art date
Application number
CL2016003260A
Other languages
English (en)
Inventor
Hugh Griffith
Christopher Mcguigan
Magdalena Slusarczyk
Michaela Serpi
Valentina Ferrari
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53499027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016003260(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of CL2016003260A1 publication Critical patent/CL2016003260A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

<p>Gemcitabina-[fenil(benzoxi-L-alaninil)]-(S/R)-fosfato; formulación farmaceutica y uso en el tratamiento del cancer.</p>
CL2016003260A 2014-06-25 2016-12-20 Profármacos de gemcitabina CL2016003260A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
IN2050MU2014 2014-06-25

Publications (1)

Publication Number Publication Date
CL2016003260A1 true CL2016003260A1 (es) 2017-10-06

Family

ID=53499027

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016003260A CL2016003260A1 (es) 2014-06-25 2016-12-20 Profármacos de gemcitabina

Country Status (29)

Country Link
US (2) US10662213B2 (es)
EP (2) EP3757112B1 (es)
JP (2) JP6982957B2 (es)
KR (2) KR102407935B1 (es)
CN (2) CN106459129B (es)
AU (2) AU2015278899B2 (es)
CA (1) CA2945938C (es)
CL (1) CL2016003260A1 (es)
CY (1) CY1123389T1 (es)
DK (1) DK3160978T3 (es)
EA (1) EA034890B1 (es)
ES (2) ES2948660T3 (es)
HR (2) HRP20230584T1 (es)
HU (2) HUE053240T2 (es)
IL (2) IL248642B (es)
LT (1) LT3160978T (es)
ME (1) ME03817B (es)
MX (2) MX2016015628A (es)
MY (1) MY183198A (es)
NZ (2) NZ765508A (es)
PH (1) PH12016502553B1 (es)
PL (1) PL3160978T3 (es)
PT (1) PT3160978T (es)
RS (1) RS60968B1 (es)
SG (2) SG11201608808TA (es)
SI (1) SI3160978T1 (es)
SM (1) SMT202000564T1 (es)
TW (2) TWI695718B (es)
WO (1) WO2015198058A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503750YA (en) 2012-11-16 2015-06-29 Univ Cardiff Process for preparing nucleoside prodrugs
JP6855248B2 (ja) 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
HRP20230584T1 (hr) 2014-06-25 2023-09-15 NuCana plc Prolijekovi gemcitabina
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106539810B (zh) 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
HRP20211812T1 (hr) 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
CN107652342A (zh) * 2016-07-23 2018-02-02 江苏万高药业股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CN110215469B (zh) * 2019-07-08 2021-11-30 绍兴市人民医院 一种治疗胆管癌的药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2595606C (en) 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
GB0821994D0 (en) 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
SG172921A1 (en) 2009-01-09 2011-08-29 Univ Cardiff Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
BR112012011784A2 (pt) 2009-11-20 2019-09-24 Clavis Pharma Asa "formulações parenterais de derivados de gencitabina".
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
HUE029022T2 (en) 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
CA2863500A1 (en) 2012-01-20 2013-07-25 Aratana Therapeutics Nv Eye drop composition
SG11201503750YA (en) * 2012-11-16 2015-06-29 Univ Cardiff Process for preparing nucleoside prodrugs
GB2517988A (en) * 2013-09-09 2015-03-11 Redx Pharma Ltd Compounds
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
RU2016125213A (ru) * 2013-11-27 2017-12-29 АЙДЕНИКС ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Нуклеотиды для лечения рака печени
JP6855248B2 (ja) * 2014-06-25 2021-04-07 ヌカナ ピーエルシー ゲムシタビン−プロドラッグを含む製剤
HRP20230584T1 (hr) 2014-06-25 2023-09-15 NuCana plc Prolijekovi gemcitabina
WO2016012781A1 (en) 2014-07-22 2016-01-28 Nucana Biomed Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EP3415149A1 (en) 2015-05-14 2018-12-19 NuCana plc Cancer treatments
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
HRP20211812T1 (hr) 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
MA51576A (fr) 2015-12-23 2020-11-18 NuCana plc Polythérapie
WO2017109444A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative

Also Published As

Publication number Publication date
CN106459129A (zh) 2017-02-22
EP3160978B1 (en) 2020-07-29
MY183198A (en) 2021-02-18
EA034890B1 (ru) 2020-04-02
TWI758728B (zh) 2022-03-21
EP3757112C0 (en) 2023-06-07
US20170107246A1 (en) 2017-04-20
KR102563040B1 (ko) 2023-08-02
HUE062474T2 (hu) 2023-11-28
JP2020152725A (ja) 2020-09-24
IL248642B (en) 2020-03-31
NZ725205A (en) 2023-12-22
PH12016502553B1 (en) 2021-10-29
AU2015278899B2 (en) 2019-07-18
HRP20230584T1 (hr) 2023-09-15
AU2019216626A1 (en) 2019-09-05
IL272724A (en) 2020-04-30
ME03817B (me) 2021-04-20
EA201692312A1 (ru) 2017-04-28
JP6970236B2 (ja) 2021-11-24
PL3160978T3 (pl) 2020-11-30
AU2015278899A1 (en) 2016-11-03
HUE053240T2 (hu) 2021-06-28
SG10201907898SA (en) 2019-09-27
IL272724B (en) 2021-06-30
SMT202000564T1 (it) 2020-11-10
MX391758B (es) 2025-03-21
KR102407935B1 (ko) 2022-06-10
CA2945938A1 (en) 2015-12-30
RS60968B1 (sr) 2020-11-30
KR20170043479A (ko) 2017-04-21
EP3757112B1 (en) 2023-06-07
PH12016502553A1 (en) 2017-04-10
CN106459129B (zh) 2020-03-31
WO2015198058A1 (en) 2015-12-30
TW201613614A (en) 2016-04-16
NZ765508A (en) 2023-12-22
EP3160978A1 (en) 2017-05-03
PT3160978T (pt) 2020-08-24
TW202033204A (zh) 2020-09-16
AU2019216626B2 (en) 2020-07-23
JP6982957B2 (ja) 2021-12-17
SG11201608808TA (en) 2016-11-29
CA2945938C (en) 2023-04-18
US11629164B2 (en) 2023-04-18
IL248642A0 (en) 2017-01-31
CN111214480A (zh) 2020-06-02
LT3160978T (lt) 2020-08-25
JP2017519014A (ja) 2017-07-13
MX2021001140A (es) 2022-04-21
EP3757112A1 (en) 2020-12-30
ES2948660T3 (es) 2023-09-15
CY1123389T1 (el) 2021-12-31
KR20220080220A (ko) 2022-06-14
DK3160978T3 (da) 2020-08-17
HRP20201264T1 (hr) 2021-02-05
MX2016015628A (es) 2017-07-04
TWI695718B (zh) 2020-06-11
ES2811268T3 (es) 2021-03-11
US10662213B2 (en) 2020-05-26
SI3160978T1 (sl) 2020-11-30
US20200262861A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
CL2016003260A1 (es) Profármacos de gemcitabina
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
ECSP15026557A (es) Compuestos y sus métodos de empleo
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
ECSP17073743A (es) Moduladores de k-ras
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
MX378273B (es) Compuestos activos hacia bromodominios.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX376329B (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
PL3186244T3 (pl) Analogi dioksolanowe urydyny w leczeniu raka
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2015002897A1 (es) Inhibidores de bace1
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
DK3380086T3 (da) Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos